Greater Southern California Node of the Clinical Trials Network

临床试验网络大南加州节点

• 批准号: 10581587
• 负责人: YIH-ING HSER
• 金额: $ 66.25万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-06-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10581587
• 关键词: Address; Area; Behavior Therapy; California; Cellular Phone; Clinical Research; Clinical Treatment; Clinical Trials Network; Collaborations; Concept Review; Data Science; Development; Drug abuse; Faculty; Generations; Goals; Health; Health Services Accessibility; Health care facility; Healthcare; Helping to End Addiction Long-term; Improve Access; Individual; Interdisciplinary Study; Intervention; Intervention Studies; Journals; Lead; Leadership; Mission; Modeling; Morbidity - disease rate; Multi-Institutional Clinical Trial; National Institute of Drug Abuse; New York; Pharmaceutical Preparations; Pharmacotherapy; Population; Population Heterogeneity; Principal Investigator; Protocols documentation; Public Health; Research; Research Infrastructure; Research Personnel; Research Priority; Research Support; Seminal; Services; Substance Use Disorder; Talents; Technology; Telemedicine; Testing; Training; Treatment Effectiveness; Treatment outcome; United States; United States National Institutes of Health; Vulnerable Populations; Work; clinical practice; clinical trial implementation; comorbidity; design; electronic health record system; health care service organization; health care settings; implementation science; implementation strategy; improved; improved outcome; innovation; innovative technologies; mHealth; meetings; mortality; opioid epidemic; opioid use disorder; overdose death; pharmacologic; protocol development; response; rural area; rural setting; student training; substance use treatment; uptake

Project Summary/Abstract The overarching goal of the Greater Southern California Node (GSCN) of the National Drug Abuse Treatment Clinical Trials Network (CTN) is to expand access to and improve outcomes of treatments for substance use disorders (SUDs)—with a special emphasis on opioid use disorder (OUD) —by collaboratively developing and testing effective and sustainable interventions for OUD that can be delivered in diverse healthcare settings. To achieve this goal, we have assembled (1) local, regional, and state-wide healthcare networks that serve millions of individuals, (2) investigators who have conducted seminal work on development and testing of pharmacological and behavioral interventions for SUDs, and (3) researchers with expertise in implementation strategies, data science, and innovative technologies to support treatment delivery and related research. Building upon investigators' past and current efforts, the specific aims of GSCN are: Aim 1. Lead and contribute to the development of new research protocols designed to increase access to treatments for OUD and to improve treatment outcomes; Aim 2. Support and participate in multi-site CTN projects and other CTN activities; and Aim 3. Disseminate research findings and provide innovative training to impact clinical practice. The GSCN research agenda will initially focus on four priority areas: (1) developing and testing effective medication and behavioral interventions for OUD and related comorbidities, (2) applying implementation science to deliver and expand OUD treatment in multiple healthcare settings, (3) leveraging eHealth (e.g., electronic health record systems) and data science for discovery and generation of innovative hypotheses and approaches to improve treatment for OUD, and (4) building on mHealth (e.g., smartphone- assisted interventions) and other technologies (e.g., telemedicine) to expand OUD treatment access and utilization. The GSCN research agenda reflects its capacity to collaboratively expand CTN efforts to develop and implement innovative approaches to improve treatment for OUD and other SUDs.

项目摘要/摘要 全国药物滥用大南加州节点(GSCN)的总体目标 治疗临床试验网络(CTN)是为了扩大获得治疗的机会并改善治疗结果 物质使用障碍(SODS)--特别强调阿片类药物使用障碍(OUD)--通过合作 开发和测试可通过多种方式交付的有效和可持续的OUD干预措施 医疗保健设置。为了实现这一目标，我们集合了(1)地方、地区和全州范围的医疗保健 服务于数百万个人的网络，(2)在发展方面开展开创性工作的调查人员 和对肥胖症的药理和行为干预的测试，以及(3)具有以下专业知识的研究人员 实施战略、数据科学和创新技术，以支持治疗提供和相关 研究。在调查人员过去和目前努力的基础上，GSCN的具体目标是：目标1.领导 并有助于开发新的研究方案，旨在增加获得治疗的机会 和改善治疗结果；目标2.支持和参与多地点CTN项目和其他 CTN活动；以及目标3.传播研究成果并提供创新培训以影响临床 练习一下。全球合作网络研究议程最初将侧重于四个优先领域：(1)开发和测试 有效的药物和行为干预对OUD及其相关合并症，(2)应用 实施科学，以在多个医疗保健环境中提供和扩展OUD治疗，(3)利用 电子健康(例如，电子健康记录系统)和数据科学，用于发现和生成创新的 改善OUD治疗的假设和方法，以及(4)建立在mHealth(例如，智能手机- 辅助干预)和其他技术(例如远程医疗)，以扩大我们的治疗机会和 利用率。全球气候变化网络研究议程反映了其合作扩大全球气候变化网络发展努力的能力。 并实施创新方法，以改善对OUD和其他肥皂泡的治疗。

项目成果

The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives.

• DOI: 10.1016/j.jsat.2021.108544
• 发表时间: 2022-03
• 期刊: Journal of substance abuse treatment
• 影响因子: 3.9
• 作者: Lin C;Clingan SE;Cousins SJ;Valdez J;Mooney LJ;Hser YI
• 通讯作者: Hser YI

Identifying patients with opioid use disorder using International Classification of Diseases (ICD) codes: Challenges and opportunities.

使用国际疾病分类 (ICD) 代码识别阿片类药物使用障碍患者：挑战和机遇。

• DOI: 10.1111/add.16338
• 发表时间: 2024
• 期刊: Addiction (Abingdon, England)
• 作者: Osterhage,KatieP;Hser,Yih-Ing;Mooney,LarissaJ;Sherman,Seth;Saxon,AndrewJ;Ledgerwood,Maja;Holtzer,CalebC;Gehring,MargaretA;Clingan,SarahE;Curtis,MeganE;Baldwin,Laura-Mae
• 通讯作者: Baldwin,Laura-Mae

Social Determinants of Health and Continuity of Medications for Opioid Use Disorder Among Patients Receiving Treatment in Rural Primary Care Settings.

在农村初级保健机构接受治疗的患者中阿片类药物使用障碍的健康和持续用药的社会决定因素。

• DOI: 10.1097/adm.0000000000001274
• 发表时间: 2024
• 期刊: Journal of addiction medicine
• 影响因子: 5.5
• 作者: Pham,Huyen;Ober,Allison;Baldwin,Laura-Mae;Mooney,LarissaJ;Zhu,Yuhui;Fei,Zhe;Hser,Yih-Ing
• 通讯作者: Hser,Yih-Ing

Disparities in digital access among American rural and urban households and implications for telemedicine-based services.

• DOI: 10.1111/jrh.12614
• 发表时间: 2022-06
• 期刊: JOURNAL OF RURAL HEALTH
• 影响因子: 4.9
• 作者: Curtis, Megan E.;Clingan, Sarah E.;Guo, Huiying;Zhu, Yuhui;Mooney, Larissa J.;Hser, Yih-Ing
• 通讯作者: Hser, Yih-Ing

Association Between Benzodiazepine and Opioid Prescription and Mortality Among Patients in a Large Healthcare System.

• DOI: 10.1097/adm.0000000000000828
• 发表时间: 2022-01-01
• 期刊: Journal of addiction medicine
• 影响因子: 5.5
• 作者: Mooney LJ;Zhu Y;Yoo CK;Wolitzky-Taylor K;Hser YI
• 通讯作者: Hser YI